Influence of antimicrobial peptide (alpha defensins; beta defensins) expression in appendicitis acuta - a prospective cross-sectional study

Influence of antimicrobial peptide (alpha defensins; beta defensins) expression in appendicitis acuta - a prospective cross-sectional study - DEFAPP-TRIAL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00024704

Enrollment

175

Registered

2021-03-05

Start date

2019-07-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K35

Interventions

Group 1: Study participants were recruited after suspected diagnosis of appendicitis acuta was diagnosed. After resection of the vermiform appendix, the required biopsy (sample collection) was perform

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suspected diagnosis on the basis of clinical appearance, blood values and/or image morphology

Exclusion criteria

Exclusion criteria: - Minority - Lack of capacity to consent - Active hepatitis C and HIV

Design outcomes

Primary

Measure	Time frame
Primary endpoint is to determine the expression levels of alpha- and beta-defensins in appendicitis acuta. The determination was performed by means of quantitative real time PCR from the postoperatively obtained appendix vermiformis resectate.	—

Secondary

Measure	Time frame
- Determination of prognostic factors for the Evaluation of the severity of appendicitis acuta	—

Countries

Germany

Contacts

Public ContactSteffen Axt

Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie, Universitätsklinikum Tübingen

Steffen.Axt@med.uni-tuebingen.de004970712981235

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026